Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral Centres

被引:68
作者
Campi, Riccardo [1 ,2 ,3 ]
Amparore, Daniele [4 ]
Capitanio, Umberto [5 ]
Checcucci, Enrico [4 ]
Salonia, Andrea [5 ,6 ]
Fiori, Cristian [4 ]
Minervini, Andrea [2 ,3 ]
Briganti, Alberto [5 ,6 ]
Carini, Marco [2 ,3 ]
Montorsi, Francesco [5 ,6 ]
Serni, Sergio [1 ,3 ]
Porpiglia, Francesco [4 ]
机构
[1] Univ Florence, Careggi Hosp, Dept Urol Robot Surg & Renal Transplantat, Florence, Italy
[2] Univ Florence, Dept Expt & Clin Med, Florence, Italy
[3] Univ Florence, Dept Urol Oncol Minimally Invas Robot Surg & Andr, Careggi Hosp, Florence, Italy
[4] Univ Turin, Div Urol, Dept Oncol, Sch Med,San Luigi Hosp, Turin, Italy
[5] IRCCS Osped San Raffaele, Urol Res Inst, Unit Urol, Div Expt Oncol, Milan, Italy
[6] Univ Vita Salute San Raffaele, Milan, Italy
关键词
Coronavirus; COVID-19; High priority; Italy; Major cancer surgery; Pandemic;
D O I
10.1016/j.eururo.2020.03.054
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The coronavirus 2019 (COVID-19) pandemic has led to an unprecedented emergency scenario for all aspects of health care, including urology. At the time of writing, Italy was the country with the highest rates of both infection and mortality. A panel of experts recently released recommendations for prioritising urologic surgeries in a low-resource setting. Of note, major cancer surgery represents a compelling challenge. However, the burden of these procedures and the impact of such recommendations on urologic practice are currently unknown. To fill this gap, we assessed the yearly proportion of high-priority major uro-oncologic surgeries at three Italian high-volume academic centres. Of 2387 major cancer surgeries, 32.3% were classified as high priority (12.6% of radical nephroureterectomy, 17.3% of nephrectomy, 33.9% of radical prostatectomy, and 36.2% of radical cystectomy cases). Moreover, 26.4% of high-priority major cancer surgeries were performed in patients at higher perioperative risk (American Society of Anesthesiologists score > 3), with radical cystectomy contributing the most to this cohort (50%). Our real-life data contextualise ongoing recommendations on prioritisation strategies during the current COVID-19 pandemic, highlighting the need for better patient selection for surgery. We found that approximately two-thirds of elective major uro-oncologic surgeries can be safely postponed or changed to another treatment modality when the availability of health care resources is reduced. Patient summary: We used data from three high-volume Italian academic urology centres to evaluate how many surgeries performed for prostate, bladder, kidney, and upper tract urothelial cancer can be postponed in times of emergency. We found that approximately two-thirds of patients with these cancers do not require high-priority surgery. Conversely, of patients requiring high-priority surgery, approximately one in
引用
收藏
页码:11 / 15
页数:3
相关论文
共 9 条
[1]  
American College of Surgeons, Standard Operating Procedure (SOP) for Triage of Suspected COVID-. 19 Patients| COVID-19| CDC Internet
[2]   Urology practice during the COVID-19 pandemic [J].
Ficarra, Vincenzo ;
Novara, Giacomo ;
Abrate, Alberto ;
Bartoletti, Riccardo ;
Crestani, Alessandro ;
De Nunzio, Cosimo ;
Giannarini, Gianluca ;
Gregori, Andrea ;
Liguori, Giovanni ;
Mirone, Vincenzo ;
Pavan, Nicola ;
Scarpa, Roberto M. ;
Simonato, Alchiede ;
Trombetta, Carlo ;
Tubaro, Andrea ;
Porpiglia, Francesco .
MINERVA UROLOGICA E NEFROLOGICA, 2020, 72 (03) :369-375
[3]  
Gillessen Sommer S., EUR UROL
[4]  
Italian Ministry of health, NUOV COR
[5]  
Mottet N, EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer
[6]   Urology in the time of corona [J].
Naspro, Richard ;
Da Pozzo, Luigi F. .
NATURE REVIEWS UROLOGY, 2020, 17 (05) :251-253
[7]   COVID-19 and Italy: what next? [J].
Remuzzi, Andrea ;
Remuzzi, Giuseppe .
LANCET, 2020, 395 (10231) :1225-1228
[8]  
Stensland K.D., EUR UROL
[9]  
World Health Organization, REP WHO CHIN JOINT M